Company Name: Proteomics International
Announcement Date: 11/11/2016
Announcement Category: Product launch/update
Announcement Content:
Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) today reached a strategic milestone in its commercialisation pathway for PromarkerD, the company's predictive test for diabetic kidney disease.
PILL signs production contract with Monash Antibody Technologies Facility
Custom antibodies will be designed to recognise the diabetic kidney disease 'fingerprints'
Strategic milestone in production of a pathology lab test
The company has signed a contract with the Monash Antibody Technologies Facility to produce the custom antibodies needed for a multiplex ELISA (Enzyme-linked immunosorbent assay), which is the precursor to a pathology lab In vitro Diagnostic (IVD) test.
The deal represents the culmination of a detailed evaluation of global manufacturing options and the required make-up of the kit's components.
This follows the successful manufacture of synthetic analogues of the biomarkers that make up the protein 'fingerprints' used to diagnose disease.
The antibodies will be designed to recognise these fingerprints and thereby provide the basis for a sensitive pathology lab assay.
Announcement URL: http://www.proteomics.com.au/wp-content/uploads/161111-ASX-release_PromarkerD-test-kit-production-deal-signed.pdf
About Proteomics International:
Proteomics International is a medical technology company specialising in providing sophisticated analytical services and developing new diagnostic tests for chronic diseases. The company’s core technology platform uses proteomics – the industrial-scale study of the structure and function of proteins. In 2015–16, PI grew its analytical services business in India, secured its first contracts in the Middle East, improved distribution channels in Japan and expanded into Central America. An ongoing partnership with InVentiv Health led to new market expansion opportunities in the US. Exports account for 40 per cent of PI’s total revenue.
Part of the PILL group.
Go to Company Profile for: Proteomics International
Announcement Contact: [email protected]
